Heart Failure Society of America and American Society for Preventive Cardiology call for prevention-first approach to reduce U.S. heart failure crisis

Heart failure remains one of the most persistent public health threats in the United States, affecting over 6 million Americans today and projected to impact more than 11 million by 2050, according to available public data. Despite significant therapeutic progress in cardiovascular medicine, nearly one in four patients is readmitted to the hospital within 30 days of discharge, and one in five dies within a year of diagnosis. The combined human toll and financial burden—estimated to exceed $30 billion annually—underscore the urgency for a fundamental shift in how the disease is addressed.

In a first-of-its-kind move, the Heart Failure Society of America (HFSA) and the American Society for Preventive Cardiology (ASPC) have jointly issued a scientific statement that reframes heart failure as a preventable condition rather than an inevitable outcome. Published in the Journal of Cardiac Failure and the American Journal of Preventive Cardiology, the paper—titled The Continuum of Prevention and Heart Failure in Cardiovascular Medicine—offers a comprehensive prevention roadmap, integrating early risk identification with multidisciplinary care strategies.

Why the joint statement marks a turning point for heart failure care in the U.S.

Historically, heart failure prevention has been addressed in fragmented ways, with most interventions beginning only after symptoms emerge. The joint HFSA–ASPC statement represents a deliberate departure from this approach by placing prevention at the forefront, spanning the entire patient journey—from healthy individuals at risk to those with advanced disease managed through left ventricular assist devices (LVADs) or heart transplants.

For decades, cardiovascular medicine has prioritized secondary and tertiary care, often reacting to clinical events rather than proactively managing risk. The new guidance calls for preventive cardiology and heart failure specialists to collaborate far earlier, breaking down silos and creating a unified, lifespan-based prevention framework. By integrating strategies such as blood pressure control, glucose management, genetic risk screening, and lifestyle modification decades before symptoms develop, the goal is to slow or even halt progression toward heart failure.

How prevention-first strategies could reshape clinical practice and healthcare economics

The economic stakes are high. Current estimates from the American Heart Association place the total cost of cardiovascular disease—including hospitalizations, pharmaceuticals, lost productivity, and post-acute care—at more than $400 billion annually. Heart failure alone accounts for a substantial portion of this figure. By shifting to a prevention-first model, healthcare systems could potentially reduce hospital readmissions, improve quality-adjusted life years (QALYs), and alleviate strain on Medicare and private insurers.

Clinically, the adoption of prevention-based protocols would mean routine cardiovascular risk assessments starting earlier in adulthood, increased use of biomarker and polygenic risk testing, and closer integration of nutrition, exercise, and mental health programs into primary care. Analysts in the healthcare policy sector note that this could trigger a ripple effect, influencing reimbursement models, hospital performance metrics, and the allocation of federal research funding toward earlier interventions.

The core principles shaping the HFSA–ASPC prevention framework

The joint statement emphasizes a broad and inclusive definition of heart failure risk factors. While traditional drivers such as hypertension, diabetes, and obesity remain central, the framework also draws attention to less frequently addressed risks, including sex-specific factors like hypertensive disorders of pregnancy and premature menopause, along with genetic predispositions, environmental exposures, and socioeconomic determinants of health. Prevention is framed as a continuum that applies across all stages of life, from at-risk but asymptomatic individuals to patients with diagnosed heart failure and those already undergoing advanced therapies. For those in earlier stages, prevention focuses on education, lifestyle optimization, and targeted intervention, while for those with established disease it includes strategies to slow progression, prevent rehospitalization, and improve overall quality of life.

The statement also advocates for the use of advanced diagnostic and predictive tools, calling on clinicians to incorporate biomarkers, polygenic risk scores, and artificial intelligence–driven models to identify high-risk patients earlier and match them with personalized intervention plans. These tools, the authors note, can help refine stratification, ensuring resources are directed toward those most likely to benefit from preventive measures. This approach is complemented by a call for team-based care models, in which cardiologists, primary care physicians, endocrinologists, dietitians, exercise physiologists, and mental health professionals collaborate within integrated care networks to ensure continuity and coordination. The authors further stress the importance of addressing health equity, urging that prevention strategies account for disparities in access, socioeconomic barriers, and cultural factors that influence both risk and treatment adherence.

Industry sentiment and potential adoption challenges

While the HFSA–ASPC statement has been welcomed by preventive cardiology advocates, adoption across the healthcare landscape may face obstacles. Experts note that fee-for-service models, which dominate U.S. healthcare, often do not incentivize preventive measures. Transitioning to value-based care models that reward reduced hospitalizations and improved patient outcomes could be essential for widespread implementation.

Institutional buy-in will also require robust training programs for clinicians, investment in diagnostic infrastructure, and patient education campaigns. Healthcare investors have pointed out that AI-driven risk stratification and genetic testing technologies—areas emphasized in the joint statement—are attracting increased venture capital interest, which could accelerate commercialization of relevant tools.

Broader implications for the cardiovascular device and biotech sectors

The prevention-first approach outlined in the statement could influence product development pipelines for medical device manufacturers and biotech companies. Firms producing LVADs, cardiac monitoring devices, and genetic testing kits may find expanded markets if preventive screening becomes standard practice.

Pharmaceutical companies focusing on heart failure therapeutics could also shift toward earlier intervention drugs targeting pre-heart failure stages, aligning with the statement’s call for upstream treatment. According to market research firm Grand View Research, the global heart failure treatment market was valued at over $13 billion in 2024 and is expected to grow steadily through 2030, driven in part by preventive care adoption.

Why this guidance matters for health systems, insurers, and policymakers

For health systems, the HFSA–ASPC framework offers a blueprint to align clinical practices with cost-saving, value-based strategies. For insurers, particularly Medicare Advantage and commercial health plans, prevention-driven care pathways could reduce costly readmissions and extend patient longevity, improving plan performance metrics.

Policymakers could also leverage the joint statement as a foundation for public health campaigns aimed at reducing the national cardiovascular burden. Similar large-scale prevention initiatives in other disease areas—such as the anti-smoking campaigns of the late 20th century—demonstrated that population-level interventions can yield measurable public health gains within a decade.

Path forward for integrating prevention into standard heart failure care

The road to implementation will require coordinated action from multiple stakeholders. Hospitals and clinics may need to restructure care teams, invest in preventive cardiology training, and integrate AI-powered risk assessment into electronic health records.

Academic medical centers are expected to play a role in validating the efficacy of the prevention framework through longitudinal studies, while community health organizations could act as early adopters, piloting programs that bring prevention into primary care settings. Experts caution that while the clinical evidence supporting prevention-first strategies is strong, changing entrenched care models will demand cultural shifts in both provider behavior and patient expectations. The HFSA and ASPC have committed to continued collaboration, with plans to release supplemental guidance and educational materials aimed at aiding implementation.